Cagrilintide and CagriSema: Amylin + GLP-1 Phase 3 Research Review
Cagrilintide is a long-acting amylin analogue that, combined with semaglutide as CagriSema, produced 20.4% mean weight loss in the Phase 3 REDEFINE 1 trial. This article covers the amylin receptor mechanism, the REDEFINE program results, NDA submission status, and research applications.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
The dominant paradigm in pharmacological obesity research has centered on the incretin axis — GLP-1 receptor agonism and its extensions into dual and triple receptor co-agonism. Cagrilintide represents a different mechanistic approach: an amylin receptor agonist that addresses satiety through a neurologically distinct pathway and, when combined with semaglutide as CagriSema, has produced weight-loss outcomes in Phase 3 trials that exceed those reported for any approved monotherapy agent. The combination is currently under FDA regulatory review following a New Drug Application submission in December 2025, making CagriSema one of the most closely watched compounds in the metabolic research pipeline.
This article examines the amylin receptor pharmacology underlying cagrilintide, the clinical evidence base from the REDEFINE trial program, and the research implications of combining amylin and GLP-1 receptor agonism.
Research reference only. All information on this page summarizes peer-reviewed scientific literature and is not intended to guide human use. See the Cagrilintide compound library entry for full pharmacokinetic data and citation index.
What is cagrilintide?
Cagrilintide is a long-acting synthetic amylin analogue developed by Novo Nordisk. Amylin (islet amyloid polypeptide, or IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Endogenous amylin regulates satiety through amylin receptors in the area postrema and nucleus tractus solitarius of the brainstem, complementing the hypothalamic and vagal mechanisms engaged by GLP-1.
The native human amylin sequence is not pharmacologically useful as a drug because it forms amyloid fibrils at physiological concentrations — the same aggregation property that contributes to beta-cell toxicity in type 2 diabetes. Cagrilintide addresses this through a series of engineered sequence modifications, and adds a long fatty-acid chain for extended half-life enabling once-weekly dosing.
Structural engineering
Cagrilintide differs from both native human amylin and pramlintide (the short-acting amylin analogue approved in 2005) through several deliberate modifications:
- 14E / 17R mutations: introduce a salt bridge that stabilizes the central helix
- 25P / 28P / 29P mutations: borrow residues from rat amylin, which does not aggregate, to prevent fibril formation
- C-terminal proline: enhances potency at the calcitonin receptor component of the amylin receptor complex
- N-terminal C20 fatty acid chain: extends plasma half-life to approximately 159–195 hours, enabling once-weekly subcutaneous dosing in human trials
The resulting molecule has significantly improved thermostability and aggregation resistance compared with native amylin, while retaining full agonist activity at amylin receptor subtypes.
Mechanism of action
Cagrilintide binds to amylin receptor subtypes AMY1R, AMY2R, and AMY3R — heteromeric complexes formed by the calcitonin receptor (CTR) combined with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3, respectively. Receptor activation engages both homeostatic satiety circuits (hypothalamic arcuate nucleus, paraventricular nucleus) and hedonic reward-related circuits (nucleus accumbens, ventral tegmental area), reducing both hunger signals and food-reward motivation.
The mechanistic distinction from GLP-1R agonism is neuroanatomical and neurochemical: amylin receptors in the area postrema activate brainstem satiety circuits that are independent of the vagal afferent pathway through which GLP-1 predominantly signals. When both pathways are activated simultaneously — as occurs with CagriSema — the combination engages a broader satiety network than either agent achieves alone, providing the mechanistic rationale for the observed synergistic weight reduction in combination trials.
CagriSema: the combination rationale
CagriSema is the fixed-combination product of cagrilintide 2.4 mg and semaglutide 2.4 mg administered as a single once-weekly subcutaneous injection. Semaglutide at 2.4 mg is the same dose used in the STEP 1 obesity trial (reported ~14.9% mean body weight reduction). The hypothesis was that adding a mechanistically distinct satiety signal via amylin receptors would produce weight reduction exceeding what either agent achieves independently.
Phase 2 data confirmed the synergy: at 20 weeks, CagriSema produced 17.1% mean weight loss versus 9.8% for semaglutide 2.4 mg monotherapy — nearly double the reduction from adding the amylin component at the same GLP-1 dose. This effect size justified Phase 3 investment across multiple indications.
Phase 3: REDEFINE 1 (obesity without type 2 diabetes)
The REDEFINE 1 trial is a Phase 3 randomized, double-blind, placebo-controlled study evaluating once-weekly CagriSema in adults with overweight or obesity without type 2 diabetes. Results were published in the New England Journal of Medicine (PMID 40544432, DOI 10.1056/NEJMoa2502081).
Key results at 68 weeks:
- 20.4% mean body weight reduction with CagriSema versus 3.0% with placebo
- 60% of CagriSema participants achieved ≥20% weight loss
- 23% achieved ≥30% weight loss
- 88% of participants with prediabetes at baseline returned to normoglycemia
- Gastrointestinal adverse events occurred in 79.6% of the CagriSema group versus 39.9% placebo, predominantly mild-to-moderate and transient
A 20.4% mean weight reduction is the highest reported for any pharmacological combination in a Phase 3 randomized controlled trial with placebo comparator as of mid-2026, exceeding tirzepatide's ~20–22% range in SURMOUNT trials (which had longer follow-up) and substantially exceeding approved semaglutide 2.4 mg outcomes (~14.9% in STEP 1).
Phase 3: REDEFINE 2 (type 2 diabetes)
REDEFINE 2 evaluated CagriSema in adults with type 2 diabetes, a population where GLP-1R agonists have established both glycemic and weight-management benefits. Results demonstrated:
- 15.7% mean weight loss with CagriSema, significantly greater than comparator arms
- Significantly improved HbA1c reduction versus comparators
- Greater proportion of participants achieving glycemic targets compared with semaglutide monotherapy
The glycemic improvement data are particularly relevant for researchers studying the interplay between beta-cell function, insulin secretion, and weight-dependent metabolic improvement, as the amylin and incretin pathways both intersect with pancreatic function.
Regulatory status
Novo Nordisk submitted a New Drug Application (NDA) to the FDA for CagriSema in December 2025, covering the obesity indication. A regulatory decision is expected in late 2026. The EMA application is under parallel review.
The NDA submission timeline makes CagriSema one of the most imminent potential approvals in the metabolic space as of mid-2026. If approved, it would be the first amylin/GLP-1 combination product on the market, establishing a new mechanistic category distinct from dual-incretin (GIP+GLP-1) and triple-agonist approaches.
Comparison: CagriSema versus the incretin class
| Feature | CagriSema | Tirzepatide | Retatrutide | Semaglutide 2.4 mg |
|---|---|---|---|---|
| Primary mechanism | Amylin receptor + GLP-1R | GIP receptor + GLP-1R | GCGR + GIP receptor + GLP-1R | GLP-1R |
| Developer | Novo Nordisk | Eli Lilly | Eli Lilly | Novo Nordisk |
| Phase 3 weight loss | 20.4% at 68w (REDEFINE 1) | ~20–22% at 72w (SURMOUNT) | 28.7% at 48w (TRIUMPH-4) | ~14.9% at 68w (STEP 1) |
| FDA NDA filed? | ✓ December 2025 | Approved | Not yet filed | Approved |
| Unique mechanistic axis | Amylin receptor (brainstem satiety) | GIP receptor (adipose + incretin) | Glucagon receptor (thermogenesis) | — |
| Prediabetes reversal data | 88% normoglycemia (REDEFINE 1) | Not reported at equivalent level | Not reported | Significant reduction |
| Combination partner | Semaglutide (fixed dose) | — | — | — |
The fundamental mechanistic contrast with tirzepatide and retatrutide is the receptor system engaged as the second pharmacological axis. Incretin combinations (GLP-1R + GIPR, or GLP-1R + GCGR) operate through G-protein coupled receptors expressed on peripheral metabolic tissues — adipocytes, hepatocytes, pancreatic cells. Cagrilintide's amylin receptor engagement is primarily central: the area postrema and brainstem satiety circuits are neurologically distinct from the peripheral metabolic targets of incretin co-agonism. This neuroanatomical distinction may explain why the combination produces additive effects despite being co-administered with a near-maximal GLP-1R agonist dose.
Cagrilintide monotherapy research
While CagriSema is the primary clinical development path, cagrilintide has also been studied as a monotherapy. Phase 2 dose-escalation data demonstrated dose-dependent weight reduction as a single agent, establishing that amylin receptor agonism contributes independently to the combination outcome rather than acting purely as a synergy enhancer. Researchers studying amylin receptor pharmacology in isolation — for instance, to probe the contribution of the AMY3R subtype to feeding behavior — can identify cagrilintide as a reference tool with defined potency and selectivity parameters.
Research applications
Appetite neuroscience: Cagrilintide's brainstem-focused mechanism makes it valuable for researchers studying the neural circuits of satiety. Its defined receptor subtype profile (AMY1R/AMY2R/AMY3R activation) enables targeted investigation of how amylin receptor subtypes contribute to homeostatic versus hedonic feeding.
Combination pharmacology design: The CagriSema data provide a template for combination pharmacology research — specifically, how mechanistically non-overlapping satiety pathways can be engaged simultaneously to produce greater-than-additive outcomes. Researchers designing combination studies involving other satiety targets (e.g., GIP receptor, NPY/AgRP, cannabinoid receptor) can use the amylin/GLP-1 synergy data as a pharmacological proof of concept.
Metabolic benchmarking: With REDEFINE 1 data published, 20.4% weight loss at 68 weeks becomes an available benchmark for new Phase 2 compounds targeting the obesity indication. Investigators estimating effect sizes for future studies will need to account for this benchmark when calculating statistical power.
Prediabetes and beta-cell research: The 88% prediabetes-reversal rate in REDEFINE 1 is among the highest reported in a weight-loss trial and raises questions about whether the amylin receptor component contributes specifically to beta-cell stress reduction beyond what weight loss alone would produce. This mechanistic question is an active area of investigation.
Regulatory and compounding status
Cagrilintide as a standalone compound and CagriSema as a combination product are both investigational as of mid-2026, pending FDA NDA review. No commercial formulation is approved. The 503A compounding status of cagrilintide is under review. Researchers sourcing cagrilintide for preclinical work must use institutional procurement channels appropriate for investigational compounds.
Visit the Cagrilintide compound library entry for pharmacokinetic parameters, ClinicalTrials.gov registry entries (REDEFINE program NCT identifiers), and the complete citation index.